Arcellx up 10% as FDA lifts clinical hold

• The US FDA lifted a clinical hold on a T-cell therapy treatment from Arcellx (NASDAQ:ACLX) for multiple myeloma.
• Shares are up 9.5% in postmarket trading.
• CEO Rami Elghandour said it updated its trial protocol, and the agency allowed expanded bridging therapies.
• Arcellx (ACLX), which is partnered with Gilead Sciences’ (GILD) Kite unit on CART-ddBCMA, said it plans to release phase 1 data from a phase 1 study later this year, and preliminary data from the phase 2 iMMagine-1 study in H2 2024.
• The company said it plans to begin marketing the drug in 2026.

More on Arcellx